Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors

[1] Coombes RC(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer NEJM 350 1081-1092

[2] Hall E(2005)Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial J Clin Oncol 23 5138-62

[3] Gibson LJ(2005)Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60-3796

[4] Paridaens R(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer NEJM 353 2747-537

[5] Jassem J(2010)American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 3784-562

[6] Delozier T(2011)Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer Breast Cancer Res Treat 126 529-310

[7] Jones SE(2008)Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 556-942

[8] Alvarez I(2011)Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer Breast Cancer Res Treat 126 295-3451

[9] Bertelli G(2012)Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer J Clin Oncol 30 936-4128

[10] Ortmann O(2009)Adjuvant hormonal therapy use among insured, low-income women with breast cancer J Clin Oncol 27 3445-2542

[1] Coombes RC(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer NEJM 350 1081-1092

[2] Hall E(2005)Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial J Clin Oncol 23 5138-62

[3] Gibson LJ(2005)Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60-3796

[4] Paridaens R(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer NEJM 353 2747-537

[5] Jassem J(2010)American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 3784-562

[6] Delozier T(2011)Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer Breast Cancer Res Treat 126 529-310

[7] Jones SE(2008)Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 556-942

[8] Alvarez I(2011)Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer Breast Cancer Res Treat 126 295-3451

[9] Bertelli G(2012)Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer J Clin Oncol 30 936-4128

[10] Ortmann O(2009)Adjuvant hormonal therapy use among insured, low-income women with breast cancer J Clin Oncol 27 3445-2542